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Objective
To describe the frequency, intensity and duration of
urological chronic pelvic pain syndrome symptom
exacerbations (‘flares’), as well as risk factors for these
features, in the Multidisciplinary Approach to the Study of
Chronic Pelvic Pain Epidemiology and Phenotyping
longitudinal study.
Participants and Methods
Current flare status (‘urological or pelvic pain symptoms that
are much worse than usual’) was ascertained at each bi-
weekly assessment. Flare characteristics, including start date,
and current intensity of pelvic pain, urgency and frequency
(scales of 0–10), were assessed for participants’ first three
flares and at three randomly selected times when they did not
report a flare. Generalized linear and mixed effects models
were used to investigate flare risk factors.
Results
Of the 385 eligible participants, 24.2% reported no flares,
22.9% reported one flare, 28.3% reported 2–3 flares, and
24.6% reported ≥4 flares, up to a maximum of 18 during the
11-month follow-up (median incidence rate = 0.13/bi-weekly
assessment, range = 0.00–1.00). Pelvic pain (mean = 2.63-
point increase) and urological symptoms (mean = 1.72) were
both significantly worse during most flares (60.6%), with
considerable within-participant variability (26.2–37.8%). Flare
duration varied from 1 to 150 days (94.3% within-participant
variability). In adjusted analyses, flares were more common,
symptomatic, and/or longer-lasting in women and in those
with worse non-flare symptoms, bladder hypersensitivity, and
chronic overlapping pain conditions.
Conclusion
In this foundational flare study, we found that pelvic pain
and urological symptom flares were common, but variable in
frequency and manifestation. We also identified subgroups of
participants with more frequent, symptomatic, and/or longer-
lasting flares for targeted flare management/prevention and
further study.
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Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) and
chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)
are characterized by persistent pelvic or bladder pain and
urological symptoms, such as urgency and frequency. The
aetiology of these conditions, collectively referred to as
urological chronic pelvic pain syndrome (UCPPS), is
unknown and both are difficult to diagnose and treat [1,2].
The conditions occur in ~1–7% of the population [3–6], and
contribute to significant reductions in physical and mental
health, sexual health and work productivity, as well as
considerable personal and societal healthcare expenditures
[4,7–11].
Similarly to many other chronic pain conditions, UCPPS
symptoms are not static, but instead fluctuate over time.
Symptom exacerbations (‘flares’) vary widely in presentation,
with pelvic pain intensity ranging from mild to severe, flare
duration from minutes to months, and flare frequency from
less than once per year to multiple times per day, based on
patient surveys and focus groups [12,13]. A similarly wide
range of flare frequency has been observed in the few
longitudinal studies conducted to date. In a previous IC/
BPS cohort study, 67.9% of participants reported no flares
over the 2-year follow-up, whereas 5.7% reported up to 3–4
flares (defined as UTI symptoms) [14]. Similarly, in our
small, previous UCPPS longitudinal study, 51.8% of
participants reported no flares over the 1-year follow-up,
whereas 12.5% reported 3–4 flares (defined as urological or
pelvic pain symptoms that are much worse than usual,
lasting at least 1 day) over the 20 days they completed
symptom diaries [15]. Both of these studies were limited,
however, to specific manifestations of flares (UTI symptoms
or day/days-long duration), and neither examined risk
factors for greater flare burden; therefore, we used data
from the Multidisciplinary Approach to the Study of
Chronic Pelvic Pain (MAPP) Epidemiology and
Phenotyping Study to describe the frequency and
characteristics of the full range of flares, and risk factors for
these features over the 1-year follow-up.
Participants and Methods
Study Design
The MAPP Epidemiology and Phenotyping Study was a 1-
year, multi-site longitudinal study designed to study the
‘usual-care’ natural history of UCPPS and to identify
subgroups of patients with possible differing aetiology and
clinical course [16,17]. Participants completed an extensive
battery of questionnaires at bi-annual in-person visits and a
shorter set at online bi-weekly assessments. The MAPP
Epidemiology and Phenotyping Study was approved by the
institutional review boards at each site and the data
coordinating centre. All participants provided written
informed consent.
Flare Assessment
Flares were assessed and characterized as part of a case-
crossover study of flare triggers embedded into the main
longitudinal study [18]. Briefly, at each bi-annual in-person
and bi-weekly assessment, participants were asked to report
their current flare status by answering the following question:
‘Are you currently experiencing a flare of your urological or
pelvic pain symptoms? By this we mean, are you currently
experiencing symptoms that are much worse than usual’
(Table S1). If participants responded affirmatively, they were
directed to a second questionnaire, the Brief Flare Risk Factor
Questionnaire [17], which included additional questions
about their: (i) flare start date to identify individual flares and
calculate a crude (truncated) estimate of flare duration; and
(ii) current levels of pelvic pain, urgency, and frequency to
characterize the intensity of participants’ pelvic pain and
urological symptoms during flares (using the maximum of
urgency and frequency to describe urological symptoms
because of their high degree of correlation). This additional
questionnaire was administered for the first three reported
flares and at three randomly selected times when participants
did not report a flare (once per 4-month period). Recalled
symptom data, averaged over the past week (which could
possibly include some flare and non-flare days), were also
used to describe symptoms during flares.
Risk Factor Assessment
Possible risk factors included study quarter; sex; age; duration
of symptoms and symptoms of IC/BPS or CP/CPPS at
baseline (men only); average non-flare pelvic pain and
urological symptom intensity from visit 3 onwards; and
baseline self-reported bladder hypersensitivity [19], whole
body pain widespreadness [20] and presence and number of
chronic overlapping pain conditions (COPCs) [21]. We also
examined pelvic pain and urological symptom trajectories
[22] from visit 3 onwards as possible correlates of flare
burden.
Statistical Analysis
For the flare frequency analyses, we limited the sample to
participants who reported their current flare status at least
three times. Crude incidence rates were calculated by dividing
the number of assessments at which participants reported a
flare (not taking into consideration flare start date, as this was
assessed for three flares only) by the number of completed
assessments per participant. Relative rates were calculated
with generalized linear models, using the number of
completed assessments as the offset, generalized estimating
equations for robust variance estimation, and Poisson,
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negative binomial or generalized Poisson distributions,
depending on the dispersion of the data [23–25]. Models
were initially adjusted for study site, sex, age, and average
non-flare pelvic pain and urological symptom intensity as
markers of participants’ overall clinical status. Adjustment for
baseline flare status, which might influence participants’
baseline phenotypic characteristics and correlate with greater
flare frequency, was also considered, but not retained, because
of its minimal influence on risk factor estimates once non-
flare symptom intensity was included in the models. Final
models were additionally adjusted for variables that remained
significantly associated with flare frequency: bladder
hypersensitivity and number of COPCs.
For the flare characteristic analyses, we limited the sample to
participants who completed the Brief Flare Risk Factor
Questionnaire at least twice, once each when they were and
were not experiencing a flare. Flares were required to have
started in the preceding 2 weeks to avoid double-counting.
Changes in symptom intensity during flares and risk factors
for more painful flares, those with worse urological
symptoms, and longer flares were estimated using linear and
generalized linear mixed effects models, clustering flares by
participant [26,27]. Cut-off points for more symptomatic
flares were determined by classification and regression tree
analyses [28] using data from our previous site-specific survey
[13]. This survey asked participants to report their average
pelvic pain, urgency, frequency (scales of 0–10), and bother
(none, only a little, some, and a lot) for flares lasting minutes,
hours and days. We used these data to perform two analyses
each for pelvic pain and urological symptoms, one to identify
cut-off points for flare symptom intensity associated with ‘a
lot’ of bother (≥7 out of 10 for pelvic pain and urological
symptoms), and a second to identify cut-off points for change
in intensity during flares associated with ‘a lot’ of bother
among participants with non-flare symptom values <7 (≥4 for
pain and urological symptoms). These two cut-off points were
then combined into one outcome, similarly to previous
depression analyses [29]. We used the median flare duration
(≥5 days) in the full MAPP study to define longer flares
rather than site-specific data because the distribution assessed
on the site-specific survey was considerably shorter than in
the full study. Within-participant variability in flare intensity
and duration was calculated as 1 minus the intra-class
correlation coefficient.
Two-sided P values <0.05 were considered statistically
significant. All analyses were performed using SAS version
9.4.
Results
Of the 424 enrolled participants, we excluded two who
became pregnant and 19 who did not provide flare status
information at least three times during follow-up, leaving 403
participants in the analysis. Forty-five percent of participants
were men and most identified as white (88.3%; Table S2).
The average age was 43.6 years and the average condition
duration was 8.60 years. At baseline, participants reported a
moderate level of UCPPS symptoms (mean = 5.08–5.56 out
of 10) and many had bladder hypersensitivity (82.9%),
extrapelvic pain (73.7%) and/or a COPC (38.0%).
Flare Frequency
Participants provided information on their flare status a mean
(range) of 17.6 (3–25 [2.0–11.8%]) times, with wide variation
in the number of flares reported (range 0–20 [19.5–0.3%]
respectively; median incidence rate 0.13/assessment).
Consistent with our previous observation of early symptom
regression in this cohort, flare frequency was considerably
higher at baseline (0.28/assessment) than later during follow-
up (0.11/assessment post-visit 12). As this higher baseline
flare frequency may not have been representative of
participants’ typical frequency, but possibly part of their
motivation to join MAPP, we limited all further analyses to
visit 3 onwards (n = 385 participants). In this more restricted
sample, we observed similarly wide variability in flare
frequency, with 24.2% of participants reporting no flares,
22.9% 1 flare, 28.3% 2–3 flares, and 24.6% ≥4 flares, up to a
maximum of 18 flares over the 11-month follow-up (0.3% of
participants; median incidence rate = 0.13/assessment, range
= 0.00–1.00/assessment; Fig. S1).
Risk Factors for Greater Flare Frequency
In unadjusted analyses, female sex; younger age; IC/BPS (vs
CP/CPPS) symptoms (men only); greater average non-flare
pelvic pain and urological symptom intensity; bladder
hypersensitivity; extrapelvic pain; several individual COPCs,
increasing number of COPCs, and any COPC; and worsening
pelvic pain and urological symptom trajectories were each
associated with greater flare frequency (Table 1). After
adjustment, findings for IC/BPS symptoms (men only),
bladder hypersensitivity, ≥2 COPCs, and worsening pain and
urological symptom trajectories remained statistically
significant.
Flare Characteristics
Among participants who completed the Brief Flare Risk Factor
Questionnaire at least twice (n = 807 non-flare and 716 flare
assessments from 297 participants), non-flare values ranged
from 0 to 10 for both pelvic pain (mean = 3.15) and urological
symptoms (mean = 3.35), with four participants reporting
values of 10 for pelvic pain and/or urological symptoms
(Table 2, Fig. 1). These values were significantly worse during
flares (mean = 5.78 for pelvic pain and 5.07 for urological
symptoms, ranges: 0–10). Almost all participants reported
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values >0 for pelvic pain and urological symptoms during
flares, except for two with all values of 0. On average,
symptoms increased by 2.63 (range: 4 to 9) for pelvic pain
and 1.72 (range: 6 to 8) for urological symptoms during
flares. Similar increases were observed for other UCPPS
symptoms and overall pain in the week before participants’
flare assessments. With respect to flare duration (reported for
579 flares), 20.0% of flares had lasted 1–2 days by the time of
participants’ flare assessment, 40.2% 3–6 days, 24.2% 7–
10 days, and 15.5% >10 days (range = 1–150 days). In general,
current pelvic pain decreased slightly, but significantly, with
increasing flare duration, whereas current urological symptoms
increased slightly with increasing duration.
Considering patterns of symptoms, most flares involved an
increase (≥1 point above non-flare symptoms) in both pelvic
pain and urological symptoms (60.6%), with smaller
percentages involving increases in pelvic pain (20.1%) or
urological symptoms only (5.8%). Four percent (4.3%) of flares
had stable symptoms and 9.2% had a decrease (Fig. 1). When
flares from the same participant were examined, a high degree
of within-participant variability was observed (pelvic pain =
37.8% of the total variance, urological symptoms = 26.2%, and
duration = 94.3%), indicating that participants did not always
experience the same intensity or duration of symptoms during
flares, but that these characteristics could vary.
Risk Factors for Flare Characteristics
In unadjusted analyses, female sex, worse non-flare pelvic
pain and urological symptom intensity, and fibromyalgia were
associated with more painful flares (Table 3). With the
exception of fibromyalgia, these factors were also associated
with flares with worse urological symptoms, as was earlier
study quarter, longer condition duration, IC/BPS symptoms
(men only), and bladder hypersensitivity. Having a stable
urological symptom trajectory was protective for flares with
worse urological symptoms. Finally, worse non-flare pain
Table 1 Relative rates and 95% CIs of flares in participants with urological chronic pelvic pain syndrome (n = 382*) in the Multidisciplinary Approach to
the Study of Chronic Pelvic Pain Epidemiology and Phenotyping Study, 2009–2013.
Crude RR (95% CI) Adjusted RR† (95% CI) Adjusted RR‡ (95% CI)
Increasing study quarter (continuous) 1.01 (0.92–1.11) 1.05 (0.96–1.15) 1.04 (0.96–1.14)
Female sex 1.48 (1.20–1.82) 1.29 (1.03–1.61) 1.16 (0.92–1.46)
Increasing age (continuous in years) 0.84 (0.75–0.94) 0.88 (0.79–0.99) 0.92 (0.82–1.03)
Increasing symptom duration (continuous in years) 0.97 (0.87–1.08) 0.95 (0.84–1.08) 0.94 (0.83–1.06)
Baseline IC/BPS vs CP/CPPS symptoms (males only) 1.42 (1.01–2.01) 1.71 (1.03–2.85) 1.62 (1.00–2.64)
Average non-flare pelvic pain intensity (continuous from 0 to 10) 1.13 (1.08–1.18) 1.02 (0.95–1.09) 1.03 (0.96–1.11)
Average non-flare urological symptom intensity (continuous from 0 to 10) 1.14 (1.09–1.19) 1.11 (1.04–1.18) 1.06 (0.98–1.14)
Bladder hypersensitivity
Neither painful filling nor urgency 1.00 1.00 1.00
Either painful filling or urgency 1.63 (1.18–2.26) 1.55 (1.12–2.15) 1.58 (1.15–2.20)
Both painful filling and urgency 2.19 (1.61–2.96) 1.75 (1.29–2.37) 1.73 (1.28–2.35)
Number of extrapelvic regions with pain§
0 1.00 1.00 1.00
1–2 1.34 (1.03–1.74) 1.21 (0.94–1.56) 1.16 (0.90–1.50)
3–7 1.34 (1.03–1.75) 1.08 (0.83–1.41) 1.00 (0.75–1.33)
COPC
Chronic fatigue syndrome 2.04 (1.53–2.73) 1.43 (1.08–1.90) 1.16 (0.82–1.63)
Fibromyalgia 1.41 (0.96–2.07) 1.01 (0.74–1.38) 0.71 (0.50–1.03)
Irritable bowel syndrome 1.22 (0.98–1.53) 1.05 (0.85–1.29) 0.96 (0.77–1.19)
Migraines 1.44 (1.13–1.83) 1.26 (0.99–1.60) 1.12 (0.83–1.51)
Temporomandibular joint disorder 1.31 (1.02–1.68) 1.08 (0.86–1.37) 0.82 (0.59–1.14)
Vulvodynia 1.41 (1.02–1.95) 1.22 (0.90–1.66) 1.15 (0.84–1.55)
Number of conditions
0 1.00 1.00 1.00
1 1.25 (0.98–1.59) 1.14 (0.88–1.48) 1.13 (0.87–1.45)
2 or more 1.82 (1.40–2.36) 1.34 (1.03–1.75) 1.30 (1.01–1.68)
Any condition 1.33 (1.07–1.64) 1.04 (0.85–1.27) 0.89 (0.70–1.14)
Pelvic pain trajectory over follow-up
Improving 1.00 1.00 1.00
Stable 0.95 (0.73–1.24) 0.83 (0.65–1.06) 0.85 (0.67–1.08)
Worsening 1.47 (1.15–1.87) 1.39 (1.10–1.75) 1.42 (1.13–1.78)
Urological symptom trajectory over follow-up
Improving 1.00 1.00 1.00
Stable 0.95 (0.73–1.23) 0.88 (0.69–1.12) 0.90 (0.71–1.14)
Worsening 1.41 (1.11–1.79) 1.34 (1.05–1.70) 1.33 (1.05–1.68)
COPC, chronic overlapping pain condition; CP/CPPS, chronic prostatitis/chronic pelvic pain syndrome; IC/BPS, interstitial cystitis/bladder pain syndrome; RR, relative rate.
*Excludes three participants who reported flares at all bi-weekly assessments. †Adjusted for site, sex, age, and average non-flare symptom intensity, as appropriate. ‡Adjusted for site,
sex, age, average non-flare symptom intensity, bladder hypersensitivity, and number of COPCs, as appropriate. §Seven extrapelvic regions (back, head, right leg, left leg, right arm,
left arm, and trunk) were created similar to previous analyses, using data from the Body Pain Inventory.
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intensity, irritable bowel syndrome, and any COPC were
associated with longer flares.
In adjusted analyses, female sex and greater non-flare pelvic
pain intensity remained significantly associated with more
painful flares, and female sex, greater non-flare urological
symptom intensity, and bladder hypersensitivity remained
significantly associated with flares with worse urological
symptoms. Older age increased the odds of flares with worse
urological symptoms. Finally, worse non-flare pain intensity,
irritable bowel syndrome, and any COPC remained
significantly associated with longer flares. Having a stable
pelvic pain trajectory was protective.
Discussion
In this foundational flare study – the largest and most
comprehensive to date – we found that pelvic pain and
urological symptom flares were common, but variable in
frequency, intensity and duration. This variability was
observed both across and within participants. We also found
that female sex, worse non-flare symptoms, and bladder
Table 2 Flare and non-flare symptoms in participants with urological chronic pelvic pain syndrome in the Multidisciplinary Approach to the Study of










Pelvic pain (range: 0–10) 287 3.15 (2.31) 5.78 (2.15) ‡ 2.63 <0.0001
Urological symptoms (maximum of urgency
and frequency, range: 0–10)
289 3.35 (2.47) 5.07 (2.69) § 1.72 <0.0001
Symptoms in the past week
Any pain or discomfort in the (%)
Women
Entrance to the vagina 173 38.5 52.9 14.4 0.0014
Vagina 174 39.2 52.2 13.0 0.004
Urethra 175 44.9 63.6 18.7 <0.0001
Men
Tip of the penis (not related to urination) 120 32.7 45.8 13.1 0.02
Testicles 120 29.2 38.2 9.0 0.11
Perineum 120 43.5 49.8 6.3 0.28
Any genital site 295 63.0 79.2 16.2 <0.0001
Number of genital sites with pain (range: 0–3) 295 1.15 (1.09) 1.53 (1.08) 0.38 <0.0001
Any pain or burning during urination 295 41.6 58.7 17.1 <0.0001
Any pain or discomfort during or after sexual intercourse 272 32.2 43.3 11.1 0.002
Any pain or discomfort with bladder filling 295 48.5 61.4 12.9 0.0006
Any pain or discomfort relieved by voiding 295 54.2 63.7 9.4 0.011
Frequency of a sensation of incomplete emptying
(0 = not at all to 5 = almost always)
295 1.81 (1.65) 2.16 (1.69) 0.35 0.007
Overall symptoms
Current symptoms
Overall whole body pain (range: 0–10)¶ 122 3.41 (2.56) 4.36 (2.59) 0.95 0.004
Symptoms in the past week
Worst pain (range: 0–10)¶ 122 5.42 (2.88) 6.51 (2.49) 1.10 0.001
Average pain (range: 0–10)¶ 120 3.88 (2.27) 4.63 (2.16) 0.74 0.009
UCPPS, urological chronic pelvic pain syndrome. *Includes a maximum of 807 non-flare values. †Includes a maximum of 716 flare values. ‡Taking flare duration into account (n =
579 flares), these values were 6.09 for 1–3 day-long flares, 5.70 for 4–5 day-long flares, 5.75 for 6–8 day-long flares, and 5.62 for >8 day-long flares (P < 0.0001). §These values
were 5.10 for 1–3 day-long flares, 5.10 for 4–5 day-long flares, 5.00 for 6–8 day-long flares, and 5.14 for >8 day-long flares (P < 0.0001). ¶Assessed by the Brief Pain Inventory,
which was administered every 2 months. Responses collected within 2 weeks of a flare/non-flare assessment were used.
Fig. 1 Flare and non-flare symptoms in participants with urological chronic pelvic pain syndrome in the Multidisciplinary Approach to the Study of
Chronic Pelvic Pain (MAPP) Epidemiology and Phenotyping Study, 2009–2013. On each bi-weekly assessment of the 1-year MAPP study follow-up,
participants were asked to report whether they were currently experience a flare of their urological or pelvic pain symptoms (i.e. ‘symptoms that are
much worse than usual’). If participants responded affirmatively, they were directed to a second questionnaire in which they were asked about their
current intensity of pelvic pain, urinary urgency and frequency on scales of 0–10. This questionnaire was completed for the first three reported flares.
Participants were also asked to complete the second questionnaire at three randomly selected times when they did not report a flare. (A) Describes
the distribution of pelvic pain intensity reported at non-flare (light pink) and flare (blue) assessments. Overlapping values are indicated in dark pink. (B)
Describes the distribution of urological symptom intensity (i.e. the maximum of urgency and frequency intensity) at non-flare (light pink) and flare (blue)
assessments. Changes in pelvic pain and urological symptom intensity during flares are described in (C and D), using the closest non-flare and flare
assessments for comparison. (E) presents the joint distribution of changes in pelvic pain and urological symptom intensity during flares.
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hypersensitivity or COPCs were independently associated
with greater flare burden, including greater flare frequency,
symptom intensity and/or duration.
To our knowledge, only two previous studies have
documented flare frequency over time in participants in
order to avoid recall inaccuracy [14,15]. Similarly to our
analysis, these studies (one of which included a small subset
of our participants) observed a wide range in flare
frequency, although one was considerably lower (67.9%, 0
flares; 5.7%, 3–4 flares) than our distribution (24.4% 0
flares; 20.5%, 3–4 flares), most likely because of its more
restrictive flare definition (i.e. UTI symptoms). It is also
possible that we double-counted flares lasting >2 weeks, as
these could have been captured on more than one bi-weekly
assessment. Nevertheless, our estimates are still probably
lower than the true frequency of flares because we did not
capture flares that occurred between bi-weekly assessments.
Our estimates also did not distinguish flares by intensity or
duration, both of which have been found to contribute to
their degree of impact and bother [12,13]. Future studies
should therefore consider using additional methods, such as
diaries or ecological momentary assessment, to obtain more
accurate estimates of flare frequency, both overall and by
flare type.
Similarly to flare frequency, our descriptive findings for flare
characteristics are consistent with those from the small
number of studies conducted to date [12,13,15]. These
studies, many of which included a small subset of our
participants, found that, although most flares involved
significant increases in both pelvic pain and urological
symptoms, they could also vary in type (pelvic pain only,
urological symptoms only, or both) and intensity (mild to
severe) of symptoms, both across and within participants.
These findings are consistent with our observations of: (i)
increases in both pelvic pain and urological symptoms in a
large proportion of flares (60.7%); (ii) wide ranges in flare
symptom intensity (0–10); (iii) wide ranges in changes in
symptom intensity during flares (6 to 9); and (iv)
considerable within-participant variability in symptom
intensity (26.2–37.8% of the total variance). Notably, our
large sample size also allowed us to observe a small number
of flares not previously described by other studies with
seemingly stable or decreasing symptom levels. These
unexpected flares may potentially be explained by: (i) the
inclusion of non-flare symptom values of 10, precluding
notable symptom increases during flares; (ii) changes in
symptoms during flares besides pelvic pain, urgency and
frequency, such as genital pain or pain with urination only;
(iii) long time lags between non-flare and flare assessments,
making these values less comparable; and (iv) participant
error. Similarly to previous studies, we also observed wide
variability in flare duration, ranging from 1 to 150 days;
however, our distribution was probably shifted more towards
longer flares than were previous surveys and focus groups
because of length-biased sampling [30] (i.e. longer flares
would be more likely to be captured on bi-weekly assessments
than shorter flares). Alternatively, our estimates may be
slightly under-estimated because flare duration was truncated
at bi-weekly assessments. More accurate estimates would
require following participants for the full duration of their
flare.
Finally, our findings for flare risk factors are consistent
with those from the limited literature on this topic to date
[13–15]. In their cohort study of patients with IC/BPS,
Stanford and McMurphy [14] observed that participants
with higher average baseline pain/urgency/frequency scores
were borderline significantly more likely to report a
UTI-symptom flare than those with lower scores, similar to
our observation of crude and lesser-adjusted positive
associations for greater non-flare symptom intensity with
flare frequency. We also found that participants with worse
non-flare symptoms were more likely to report flares with
greater symptom intensity and duration (pelvic pain only),
and that those with worsening pelvic pain and urological
symptom trajectories were more likely to report greater
flare frequency, consistent with focus group participant
reports that non-flare and flare symptoms worsen and
improve together, i.e. that when their condition is ‘bad’,
they experience worse non-flare symptoms, as well as more
frequent, symptomatic and longer flares [12]. An
additional novel finding from the present study was that
associations between non-flare symptoms and flare
frequency attenuated after adjustment for bladder
hypersensitivity and number of COPCs, suggesting they
may have been explained by these two characteristics rather
than by a link between worse non-flare symptoms and
greater flare frequency; for instance, as a marker of overall
worse clinical status.
With respect to sex, we previously observed that women were
more likely to report days-long flares [13,15] and less likely
to report minutes-long flares than men in minimally adjusted,
site-specific analyses [13]. As the present study design may
have been more likely to capture day(s)- rather than minutes-
long flares, we believe these previous findings are consistent
with our crude and lesser-adjusted observations of greater
flare frequency among women than men and, at least, not
inconsistent with our observation of no difference in flare
duration by sex among the sample of longer flares likely
captured by our study design.
Further novel findings from the present study were as follows:
(i) that associations between female sex and greater flare
frequency attenuated after adjustment for bladder
hypersensitivity and COPCs, suggesting that they may have
been explained by these two factors; and (ii) that women
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were independently more likely to report greater flare
symptom intensity than men.
In addition to non-flare symptoms and sex, we found that
participants with bladder hypersensitivity or COPCs (various
individual, any, or multiple COPCs), but not extrapelvic pain,
had greater flare frequency, worse urological symptoms
during flares (bladder sensitivity only), and longer flares
(COPCs only) in adjusted analyses. These novel, but slightly
contradictory findings suggest that both peripheral and
central pain mechanisms may potentially contribute to flare
burden. Finally, although some associations did not persist in
adjusted analyses, this does not mean that certain subgroups
did not experience greater flare burden, only that their
burden was more related to their bladder hypersensitivity and
COPCs than to other characteristics.
Although the present study is the largest and most detailed
cohort study of flares to date, it is still limited by its use of
data collected for a different research purpose (i.e. to identify
flare triggers with purposefully minimal ascertainment/
characterization of flares). As such, we did not have
information on flares that occurred between bi-weekly
assessments, the full duration of flares, or characteristics of all
flares (only a maximum of three flares/participant). These
limitations reduced our ability to: (i) describe the frequency
of flares overall and by symptom intensity and duration; (ii)
describe the full distribution of flare intensity and duration;
and (iii) detect associations, especially for flare intensity and
duration, as the 1–3 flares included per participant may not
have been representative of their typical flare experience.
Finally, a further major limitation is our minimal collection
of information on UCPPS therapies, precluding analysis of
their influence on flare burden.
In summary, we found that the majority of participants
experienced at least one flare of their pelvic pain and
urological symptoms during the 11-month follow-up, with
wide variability in flare frequency, intensity, and duration
between and within participants. In general, flares were
independently more common, symptomatic, and/or longer-
lasting in women, and in those with worse non-flare
symptoms, bladder hypersensitivity, or COPCs. Together,
these findings provide foundational, descriptive information
on flares and identify patient subgroups to target and study
further for flare management and prevention.
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Fig. S1. Frequency of urological chronic pelvic pain
syndrome flares in the Multidisciplinary Approach to the
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of the MAPP study, participants were asked to report
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urological or pelvic pain symptoms (i.e. ‘symptoms that are
much worse than usual’). The percentage of participants who
reported each number of flares over the last 11 months of the
1-year study is plotted.
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